In a significant strategic move, Suven Pharma announced a merger with Cohance Lifesciences in early 2024. This merger aims to enhance Suven's capabilities in the CDMO sector, with the combined entity targeting EBITDA margins in the mid-30s. The integration is expected to create synergies that will bolster Suven's position in the global pharmaceutical landscape Suven has been actively expanding its global footprint. The company's subsidiary, Casper Pharma, received a positive nod from the USFDA, concluding an inspection without any observations. This development not only validates Suven's compliance with international standards but also opens avenues for increased business in regulated market